Source: International Congress 2018 – Studies on the mechanisms underlying airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Rinaldi (London, United Kingdom), B. Dennis (London, United Kingdom), G. Houseley (London, United Kingdom), O. Shah (London, United Kingdom), M. Loebinger (London, United Kingdom). Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments. 4407

Member's Comments

No comment yet.

Related content which might interest you: Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Changes in inhalation therapy after combined assessment of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Methodological issues in therapeutic trials of COPD Source: Eur Respir J 2008; 31: 927-933 Year: 2008 Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Long-term safety of bilateral targeted lung denervation in patients with COPD in a single procedure Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more Year: 2015 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Are current treatment recommendations suited to elderly patients with asthma or COPD? Source: Eur Respir Mon; 2009: 43: 267–285 Year: 2009 Based on what parameters of clinical remission should inhaled corticosteroids be stopped in children with asthma? Source: Annual Congress 2013 –The best of paediatric asthma and allergy Year: 2013 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006 An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 The parameters that may affect inhalation therapy success in elderly COPD and asthma patients Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Compliance with nebulized therapy in patients with chronic lung disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Predicting treatment outcomes following an exacerbation of airways disease Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019